ReviewCell death & disease2026
RNA splicing in cancer cell death regulation: shedding light on the molecular mechanisms and potential clinical applications.
Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alternative splicing (AS) is a ubiquitous posttranscriptional regulatory mechanism in eukaryotes through which proteins with various structures and functions are produced from a single pre-mRNA. It is performed by the spliceosome and regulated by both cis-acting elements and trans-acting splicing factors. The common modes of regulatory cell death (RCD) include apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, and dysregulation of these cell death modes can lead to tumorigenesis. The abnormal expression of spliceosome components and splicing factors, or aberrant splicing events, modulates RCD and contributes to the occurrence and progression of cancer. This review focuses on the roles of AS in tumour RCD and the underlying mechanism through which AS modulates different modes of RCD. Moreover, we summarise some potential clinical applications of targeting AS-RCD axes. This review offers systematic and mechanistic insights into tumorigenesis from the perspectives of AS and RCD, and the ultimate objective is to translate these findings into targeted therapies for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.